ArticleFrontiers in microbiology2025
Polysaccharide from
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Methods: In this study, a mouse model of diphenoxylate-induced functional constipation was established. Meanwhile, the laxative effect of TKP on the fecal excretion function, intestinal inflammatory response, neurotransmitter secretion and gut microbiota composition were evaluated. Results: Treatment with the TKP alleviated the constipation-associated pathological symptoms in mice through enhancing the gastrointestinal (GI) transit ratio and improving defecation function. Moreover, TKP supplementation modulated the secretion levels of neurotransmitters in the serum of mice, elevating excitatory neurotransmitters (SP, MTL and ACH), while suppressing inhibitory neurotransmitters (NO, VIP and ET-1). Additionally, TKP reduced the level of MDA, and enhanced the activities of SOD and GSH-Px, effectively attenuating oxidative stress. Under TKP administration, colonic levels of pro-inflammatory cytokines (IL-6, IL-1β and TNF-α) were significantly suppressed, while upregulating the expression of tight junction proteins (ZO-1 and occludin). Crucially, TKP increased the production of short-chain fatty acids (SCFAs), and modulated the gut microbiota by restoring its abundance and diversity in constipated mice. Conclusion: Collectively, these findings demonstrated that TKP could ameliorate diphenoxylate-induced functional constipation in mice, providing a pharmacological foundation for its development as a novel therapeutic agent against constipation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.